Summary
Gilead Sciences, Inc. (GILD) has filed an 8-K report on August 8, 2024, to announce its financial results for the quarter ended June 30, 2024. The report primarily references an attached press release (Exhibit 99.1) which contains detailed financial information. Investors should note that Gilead presents its financial data on both a U.S. GAAP and a non-GAAP basis. Management believes the non-GAAP figures provide additional useful insights for investors, complementing the official GAAP statements, and are used internally for operational and strategic planning. A reconciliation of GAAP to non-GAAP measures is available within the press release. While the specific financial figures are detailed within the referenced press release and not fully reproduced in the 8-K text itself, the filing serves as the official notification to the market regarding these results. Investors are encouraged to review Exhibit 99.1 for comprehensive details on revenue, earnings, and other key performance indicators for the second quarter of 2024, as well as management's commentary and outlook.
Key Highlights
- 1Gilead Sciences (GILD) released its Q2 2024 financial results via an 8-K filing on August 8, 2024.
- 2The filing primarily references Exhibit 99.1, a press release containing the detailed financial results for the quarter ended June 30, 2024.
- 3Gilead presents financial information using both U.S. GAAP and non-GAAP measures.
- 4Management believes non-GAAP figures are valuable for investors and used internally for planning.
- 5A reconciliation between GAAP and non-GAAP financial information is provided in the press release (Exhibit 99.1).
- 6The information furnished in this 8-K is not considered 'filed' for the purposes of Section 18 of the Exchange Act.